Dapagliflozin for heart failure: is it a class effect?

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Sodium-glucose cotransporter 2 (SGLT2) inhibitors are primarily used for Type 2 diabetes mellitus management.
• Recent approvals and label changes highlight the expanding role of SGLT2 inhibitors in cardiovascular care.
• Dapagliflozin is now approved for managing worsening cardiovascular events in adults with heart failure with reduced ejection fraction.

Purpose of the Study:

• To review the current understanding of SGLT2 inhibitors in heart failure management.
• To highlight the cardiovascular benefits of dapagliflozin beyond its glucose-lowering effects.
• To discuss the potential and current limitations in the therapeutic application of other SGLT2 inhibitors in heart failure.

Main Methods:

• Literature review of clinical trials and regulatory approvals concerning SGLT2 inhibitors and heart failure.
• Analysis of the mechanisms underlying the cardiovascular benefits of SGLT2 inhibitors.
• Comparative overview of different SGLT2 inhibitors (dapagliflozin, canagliflozin, empagliflozin, ertugliflozin) in heart failure.

Main Results:

• Dapagliflozin has demonstrated efficacy in reducing cardiovascular events, including deaths and hospitalizations, in patients with heart failure with reduced ejection fraction.
• Canagliflozin's label was updated to include risk reduction for heart failure hospitalization in specific patient populations.
• The cardiovascular benefits of dapagliflozin appear to be independent of its glucose-lowering and SGLT2-inhibiting effects, suggesting novel mechanisms of action.

Conclusions:

• SGLT2 inhibitors, particularly dapagliflozin, represent a significant advancement in heart failure management.
• Further research is needed to fully delineate the role of empagliflozin and ertugliflozin in heart failure.
• The pleiotropic effects of SGLT2 inhibitors offer a promising therapeutic avenue for cardiovascular disease.